We had the pleasure of sitting down with James Lanthier, CEO of Mindset Pharma (CSE: MSET) (OTCQB: MSSTF). We discussed some very exciting news – the company was recently approved by the MHRA to fast track their lead candidate MSP-1014 to Phase II clinical trials. James also shared the story of their patents for non-hallucinogenic, non-tryptamine psychedelics and his thoughts on the rapid progress of the psychedelic movement. He also shared Mindset Pharma’s edge – the buildout of a diverse library of intellectual property.
0:00 Fast tracking MSP-1014 to Phase II Clinical Trials
2:47 Mindset Pharma’s Edge
4:35 Diverse Portfolio of Drugs
6:31 Patents for Non-Hallucinogenic, Non-Tryptamine Compounds
9:06 The Controversy with Psychedelics without the High
11:12 The Rapid Pace of Psychedelics Advancement
Ecora (LSE:ECOR)(TSX:ECOR)(OTCQX:ECRAF) notes the announcement on 4 September by Vale Base Metals that it has…
Highlights • A$14.1M Entitlement Offer received strong demand from Australian, Canadian and international shareholders •…
Ecora Resources PLC (LSE:ECOR)(TSX:ECOR)(OTCQX:ECRAF) announced half year results for the six months ended 30 June…
First Nordic Metals Corp. (TSXV: FNM) (FNSE: FNMC SDB) (OTCQB: FNMCF) (FRA: HEG0) announced the…
Ecora (LSE/TSX: ECOR, OTCQX: ECRAF) announced that it has agreed to sell a wholly-owned subsidiary,…
Power Metallic Mines Inc. (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV) announced the appointment of Seamus…